A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma

A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma

Capsule Summary The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitaz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-12, Vol.140 (6), p.1716-1718
Hauptverfasser: Kaler, Maryann, C.R.N.P, Barochia, Amisha V., M.B.B.S., M.H.S, Weir, Nargues A., M.D, Cuento, Rosemarie A., C.R.N.P, Stylianou, Mario, Ph.D, Roth, Mark J., M.D, Filie, Armando C., M.D, Vaughey, Ellen C., M.D, Nathan, Steven D., M.D, Levine, Stewart J., M.D
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
Clinical trials
Corticosteroids
Diabetes
Drug dosages
Edema
Inflammation
Laboratories
Ligands
Pioglitazone
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Capsule Summary The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe asthma.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.05.033